PubMed

The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes.

Huang ES, Shook M, Jin L, Chin MH, Meltzer DO.

Diabetes Care. 2006 Feb;29(2):259-64.PMID: 16443870 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.

CDC Diabetes Cost-effectiveness Group.

JAMA. 2002 May 15;287(19):2542-51.PMID: 12020335 [PubMed - indexed for MEDLINE]Related articlesFree article

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.PMID: 16545208 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China.

Xie X, Vondeling H.

Value Health. 2008 Mar;11 Suppl 1:S23-32.PMID: 18387063 [PubMed - indexed for MEDLINE]Related articles

Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia.

Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Copley-Merriman C, Maier W, Dong F, Manninen D, Zbrozek AS, Kotsanos J, Garfield SA, Harris M.

Diabetes Care. 1997 May;20(5):735-44.PMID: 9135935 [PubMed - indexed for MEDLINE]Related articles

Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland.

Brändle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P, Valentine WJ.

Int J Clin Pharmacol Ther. 2009 Aug;47(8):501-15.PMID: 19640359 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study.

Wake N, Hisashige A, Katayama T, Kishikawa H, Ohkubo Y, Sakai M, Araki E, Shichiri M.

Diabetes Res Clin Pract. 2000 Jun;48(3):201-10.PMID: 10802159 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.

Tunis SL, Minshall ME, Conner C, McCormick JI, Kapor J, Yale JF, Groleau D.

Curr Med Res Opin. 2009 May;25(5):1273-84.PMID: 19366302 [PubMed - indexed for MEDLINE]Related articles

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.PMID: 17999840 [PubMed - indexed for MEDLINE]Related articlesFree article

Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada.

Grima DT, Thompson MF, Sauriol L.

Pharmacoeconomics. 2007;25(3):253-66.PMID: 17335310 [PubMed - indexed for MEDLINE]Related articles

Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.

Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ.

Curr Med Res Opin. 2007 Mar;23(3):609-22.PMID: 17355742 [PubMed - indexed for MEDLINE]Related articles

Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72).

Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR; UKPDS 72 United Kingdom Prospective Diabetes Study.

Diabetologia. 2005 May;48(5):868-77. Epub 2005 Apr 15.PMID: 15834550 [PubMed - indexed for MEDLINE]Related articles

Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia.

Cohen N, Minshall ME, Sharon-Nash L, Zakrzewska K, Valentine WJ, Palmer AJ.

Pharmacoeconomics. 2007;25(10):881-97.PMID: 17887808 [PubMed - indexed for MEDLINE]Related articles

PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.

Valentine WJ, Bottomley JM, Palmer AJ, Brändle M, Foos V, Williams R, Dormandy JA, Yates J, Tan MH, Massi-Benedetti M; PROactive Study Group.

Diabet Med. 2007 Sep;24(9):982-1002. Epub 2007 Jun 25.PMID: 17593245 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.

Brändle M, Azoulay M, Greiner RA.

Int J Clin Pharmacol Ther. 2007 Apr;45(4):203-20.PMID: 17474539 [PubMed - indexed for MEDLINE]Related articles

Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom.

Woehl A, Evans M, Tetlow AP, McEwan P.

Cardiovasc Diabetol. 2008 Aug 11;7:24.PMID: 18694484 [PubMed - indexed for MEDLINE]Related articlesFree article

The cost-effectiveness of screening for type 2 diabetes. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention.

[No authors listed]

JAMA. 1998 Nov 25;280(20):1757-63. Erratum in: JAMA 1999 Jan 27;281(4):325. PMID: 9842951 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group.

Gray A, Raikou M, McGuire A, Fenn P, Stevens R, Cull C, Stratton I, Adler A, Holman R, Turner R.

BMJ. 2000 May 20;320(7246):1373-8.PMID: 10818026 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).

Clarke P, Gray A, Adler A, Stevens R, Raikou M, Cull C, Stratton I, Holman R; UKPDS Group. United Kingdom Prospective Diabetes Study.

Diabetologia. 2001 Mar;44(3):298-304.PMID: 11317659 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of insulin analogues for diabetes mellitus.

Cameron CG, Bennett HA.

CMAJ. 2009 Feb 17;180(4):400-7.PMID: 19221353 [PubMed - indexed for MEDLINE]Related articlesFree article